No profile data available.
Immunome, Inc. (IMNM) is a healthcare company in the additional cancer treatment drugs industry, based in Bothell, United States, with about 247 full-time employees.
It reported revenue of $6.94 million for fiscal year 2025, down 23.2% from fiscal year 2024, and net income of -$212.39 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $2.31 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Immunome reported $6.94 million in revenue for fiscal year 2025, down 23.2% from $9.04 million in fiscal year 2024. In Q2 2026 revenue was $0.
$2.31 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Enliven Therapeutics, Inc. (ELVN), Zai Lab Limited (ZLAB), Hutchmed (China) Limited (HCM), Zymeworks Inc. (ZYME).